Latest Administration News

ADX Energy reports a 17% production dip in Q3 2025 due to well downtime but boosts sales revenue by 23%, while advancing drilling plans and acquiring key infrastructure.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

Kingsrose Mining advances exploration in Norway’s Finnmark region with new geophysical anomalies, while navigating permitting challenges in Finland and focusing on strategic M&A under new leadership.

Australian Pacific Coal’s Dartbrook Mine has entered voluntary administration and receivership, with the company’s interest now considered to hold no value amid mounting secured debt pressures. Despite this, the company remains solvent with limited cash reserves and continues to assess its next steps.

Resolution Minerals Ltd is set to acquire a processing mill and tungsten stockpiles adjacent to its Horse Heaven Project in Idaho, aiming to accelerate U.S. production of critical metals antimony and tungsten.

Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Cooper Metals is gearing up for drilling at its Mt Isa East copper-gold project while divesting a majority stake in its Gilberton Gold Project to Sybella Metals, maintaining a solid cash position to fund exploration.

SRJ Technologies has made significant strides in its three-year growth plan, securing a $6 million joint venture with a Middle East National Oil Company and raising £1.4 million to fund its regional expansion.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

Immuron Limited reports progress on its IMM-529 FDA application and a delay in Travelan® clinical trial results due to a U.S. government shutdown, with key data now expected in late November.

Anagenics Limited reports a notable improvement in operating cash outflows for 1Q26, driven by cost efficiencies and strong brand performance, with Bouf Haircare on track to exceed $9 million in sales.